Karolinska Development
1.108
SEK
+1.65 %
KDEV
NASDAQ Stockholm
Investment
Financials
Less than 1K followers
+1.65%
+6.13%
+16.26%
-6.73%
-23.59%
-37.05%
-72.3%
-63.84%
-96.87%
Karolinska Development is a Nordic investment company in the life science sector. The company focuses on identifying medical innovations to create and develop companies that further develop such innovations into differentiated products. Karolinska Development's portfolio consists of a number of companies focused on developing treatment methods for diseases that are classified as life-threatening and serious. The largest business operations are in the Nordic market.
Read moreMarket cap
299.25M SEK
Turnover
204.78K SEK
Revenue
2.01M
EBIT %
-174.63 %
P/E
55.4
Dividend yield-%
-
Financial calendar
14.2
2025
Annual report '24
30.4
2025
Interim report Q1'25
15.5
2025
General meeting '25
ShowingAll content types
Karolinska Development’s portfolio company AnaCardio raises SEK 205 million and reports positive Phase 1b data of AC01
Karolinska Development’s portfolio company Umecrine Cognition raises MSEK 23.8 to continue clinical development of golexanolone
Join Inderes community
Don't miss out - create an account and get all the possible benefits
Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools